Cure Rates Hold Up Across Genetic Status For Vertex's Telaprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Retrospective analyses of data from pivotal studies in both naïve and experienced patients showed patients from all three possible genotypes had substantial improvements with telaprevir, Vertex reported at EASL.